At the core of Rapafusyn’s platform are its proprietary diverse libraries of FKBP-binding bi-functional macrocycles (rapafucins). These rapafucin-FKBP complexes then present the disease-target-specific “effector domain” of the macrocycles to modulate both proven and challenging disease targets.
We are a near-clinical stage company uniquely positioned in the biotech industry for its validated and differentiated “drug discovery machine” assembled upon its proprietary, bi-functional “molecular glue” macrocycle platform.
We utilize this platform for internal drug discovery and external partnering to discover and develop novel therapeutics for underserved diseases of high unmet needs.